To evaluate the DNA repair protein MRE11 as a prognostic biomarker, a standardized CLIA-eligible AQUA15 assay was used to quantitatively measure normalized MRE11 expression in pretreatment tumor tissues from patients enrolled in 6 prospective NRG/RTOG trimodality therapy clinical trials. This evidence concerns the gene XRCC6P5 and neoplasm.